

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 080060-0002 (Formerly 302018.3003-100)		APPLICATION NO. 10/006,562			
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (08/24/2005)  (Use several sheets if necessary)		APPLICANT Salomon, Daniel R. & Cramer, Donald V.					
		FILING DATE December 5, 2001		GROUP ART UNIT 1654			
U.S. PATENT DOCUMENTS							
EXAM- -NER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AM	BA	Supplementary European Search Report Dated 08 Feb 2005, Application No. EP 02 80 4721					
	BB	Aranda JM Jr, Hill J., Cardiac transplant vasculopathy. Chest. 2000 Dec;118(6):1792-800.					
	BC	Bueno V, Pestana JO. The role of CD8+ T cells during allograft rejection. Braz J Med Biol Res. 2002 Nov;35(11):1247-58.					
	BD	Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998 Jun 1;101(11):2309-18.					
	BE	Choy JC, Kerjner A, Wong BW, McManus BM, Granville DJ. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am J Pathol. 2004 Jul;165(1):127-33.					
	BF	Demetris, et al., Pathophysiology of Chronic Allograft Rejection CME, March 29, 2000, <a href="http://www.medscape.com/viewprogram/336_pnt">http://www.medscape.com/viewprogram/336_pnt</a> , visited 7/21/2005, p 1-71.					
	BG	Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Bonavida B, Ardehali A. Role of CD8+ lymphocytes in chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg. 2002 Apr;123(4):803-9.					
	BH	Grieb P, Ryba M, Janczewski W, Sawicki J, Jagielski J, Andrychowski J. 2-Chloro-2'-deoxyadenosine (2-CdA) combined with cyclosporine A successfully prevents rejection of fetal brain stem allograft in rabbits. Arch Immunol Ther Exp (Warsz). 1994;42(1):43-6.					
	BI	He C, Schenk S, Zhang Q, Valujskikh A, Bayer J, Fairchild RL, Heeger PS. Effects of T cell frequency and graft size on transplant outcome in mice. J Immunol. 2004 Jan 1;172(1):240-7.					
	BJ	Hollenberg SM, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Oberoi M, Johnson MR, Costanzo MR. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 2001 Dec 18;104(25):3091-6.					
	BK	Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med. 2000;1(3):166-171.					
	BL	Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004 Jan;23(1):159-71.					
AM	BM	Koh KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC, Tellides G, Pober JS. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest. 2004 Sep;114(6):846-56.					

Abdel A. Mohamed

1/19/06

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (08/24/2005)  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 080060-0002 (Formerly 302018.3003-100)	APPLICATION NO. 10/006,562				
		APPLICANT Salomon, Daniel R. & Cramer, Donald V.					
		FILING DATE December 5, 2001	GROUP ART UNIT 1654				
U.S. PATENT DOCUMENTS							
EXAM- -NER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Am	BN	Kouwenhoven EA, IJzermans JN, de Bruin RW. Etiology and pathophysiology of chronic transplant dysfunction. Transpl Int. 2000;13(6):385-401.					
↑	BO	Mehra MR, Ventura HO, Smart FW, Stapleton DD, Collins TJ, Ramee SR, Murgu JP, White CJ. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J. 1995;22(2):138-44					
↑	BP	Oberhuber G, Schmid T, Thaler W, Kaltenbacher A, Schirmer M, Liliemark J, Herbst P, Geisen F, Margreiter R, Konwalinka G. Evidence that 2-chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. Transplantation. 1994 Sep 27;58(6):743-5.					
↑	BQ	Shapiro R. Low toxicity immunosuppressive protocols in renal transplantation. Keio J Med. 2004 Mar;53(1):18-22.					
↑	BR	Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4051-6.					
↓ Am	BS	Slachta CA, Jeevanandam V, Goldman B, Lin WL, Plattsoucas CD. Coronary arteries from human cardiac allografts with chronic rejection contain oligoclonal T cells: persistence of identical clonally expanded TCR transcripts from the early post-transplantation period (endomyocardial biopsies) to chronic rejection (coronary arteries). J Immunol. 2000 Sep 15;165(6):3469-83.					

Abdel A. Mohamed

1/19/06

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 080060-0002 (Former 302018.3003-100)		APPLICATION NO. 10/006,562	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (7/25/2005)  (Use several sheets if necessary)		APPLICANT Salomon, Daniel R. & Cramer, Donald V.			
		FILING DATE December 5, 2001		GROUP ART UNIT 1653 1654	
U.S. PATENT DOCUMENTS					
EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
BA	Supplementary European Search Report Dated 08 Feb 2005, Application No. EP 02 80 4721				
BB	Aranda JM Jr, Hill J., Cardiac transplant vasculopathy. Chest. 2000 Dec;118(6):1792-800.				
BC	Bueno V, Pestana JO. The role of CD8+ T cells during allograft rejection. Braz J Med Biol Res. 2002 Nov;35(11):1247-58.				
BD	Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998 Jun 1;101(11):2309-18.				
BE	Choy JC, Kerjner A, Wong BW, McManus BM, Granville DJ. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am J Pathol. 2004 Jul;165(1):127-33.				
BF	Demetris, et al., Pathophysiology of Chronic Allograft Rejection CME, March 29, 2000, <a href="http://www.medscape.com/viewprogram/336_pnt">http://www.medscape.com/viewprogram/336_pnt</a> , visited 7/21/2005, p 1-71.				
BG	Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Bonavida B, Ardenhall A. Role of CD8+ lymphocytes in chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg. 2002 Apr;123(4):803-9.				
BH	Grieb P, Ryba M, Janczewski W, Sawicki J, Jagielski J, Andrychowski J. 2-Chloro-2'-deoxyadenosine (2-CdA) combined with cyclosporine A successfully prevents rejection of fetal brain stem allograft in rabbits. Arch Immunol Ther Exp (Warsz). 1994;42(1):43-6.				
BI	He C, Schenk S, Zhang Q, Valujskikh A, Bayer J, Fairchild RL, Heeger PS. Effects of T cell frequency and graft size on transplant outcome in mice. J Immunol. 2004 Jan 1;172(1):240-7.				
BJ	Hollenberg SM, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Oberoi M, Johnson MR, Costanzo MR. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 2001 Dec 18;104(25):3091-6.				
BK	Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med. 2000;1(3):166-171.				
BL	Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004 Jan;23(1):159-71.				
BM	Koh KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC, Tellides G, Poer JS. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest. 2004 Sep;114(6):846-56.				

Abdel A. Mohamed

1/19/06

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 080060-0002 (Former 302018.3003-100)		APPLICATION NO. 10/006,562	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (7/25/2005) <b>JUL 27 2005</b> (Use several sheets if necessary)		APPLICANT Salomon, Daniel R. & Cramer, Donald V.			
		FILING DATE December 5, 2001		GROUP ART UNIT 1655/654	
U.S. PATENT DOCUMENTS					
EXAM- -NER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
BN	Kouwenhoven EA, IJzermans JN, de Bruin RW. Etiology and pathophysiology of chronic transplant dysfunction. Transpl Int. 2000;13(6):385-401.				
BO	Mehra MR, Ventura HO, Smart FW, Stapleton DD, Collins TJ, Ramee SR, Murgu JP, White CJ. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J. 1995;22(2):138-44.				
BP	Oberhuber G, Schmid T, Thaler W, Kaltenbacher A, Schirmer M, Liliemark J, Herbst P, Geisen F, Margreiter R, Konwalinka G. Evidence that 2-chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. Transplantation. 1994 Sep 27;58(6):743-5.				
BQ	Shapiro R. Low toxicity immunosuppressive protocols in renal transplantation. Keio J Med. 2004 Mar;53(1):18-22.				
BR	Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4051-6.				
BS	Slachta CA, Jeevanandam V, Goldman B, Lin WL, Platsoucas CD. Coronary arteries from human cardiac allografts with chronic rejection contain oligoclonal T cells: persistence of identical clonally expanded TCR transcripts from the early post-transplantation period (endomyocardial biopsies) to chronic rejection (coronary arteries). J Immunol. 2000 Sep 15;165(6):3469-83.				

*Abdel A Mohamed*

*1/19/06*